Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4345MR)

This product GTTS-WQ4345MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4345MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ257MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ3328MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ14503MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ13216MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ14516MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ14482MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ9502MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ7413MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW